Emerging strategies for lowering serum phosphorous in patients with end-stage renal disease

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 14, 2006, Pages 1897-1905

  Ashfaq, Akhtar ^a   Gitman, Michael ^a   Singhal, Pravin C ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Dialysis; End stage renal disease; Hyperphosphataemia; Phosphate binders; Vascular calcifications

Indexed keywords

ALUMINUM CARBONATE; ALUMINUM HYDROXIDE; ALUMINUM SALT; AMITRIPTYLINE; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM PHOSPHATE; CALCIUM SALT; CINACALCET; CIPROFLOXACIN; CITRATE CALCIUM; DISODIUM HYDROGEN PHOSPHATE; KETOCONAZOLE; LANTHANUM CARBONATE; MAGNESIUM CARBONATE; MAGNESIUM HYDROXIDE; MAGNESIUM SALT; NORTRIPTYLINE; PHOSPHATE BINDING AGENT; PHOSPHOROUS ACID; SEVELAMER; VITAMIN D; VITAMIN D DERIVATIVE;

ABDOMINAL PAIN; ARTERY CALCIFICATION; COLONOSCOPY; DEMENTIA; DIABETES MELLITUS; DIALYSIS; DIARRHEA; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG INDICATION; DRUG POTENTIATION; DRUG SOLUBILITY; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART VALVE STENOSIS; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERMAGNESEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; INTERMETHOD COMPARISON; INTERSTITIAL NEPHRITIS; KETOACIDOSIS; KIDNEY CALCIFICATION; KIDNEY FAILURE; LACTIC ACIDOSIS; MICROCYTIC ANEMIA; MORBIDITY; MORTALITY; MYOPATHY; NAUSEA; OSTEOMALACIA; PATHOPHYSIOLOGY; PREDICTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; STOMACH PH; THROMBOSIS; TREATMENT OUTCOME; VOMITING;

ADULT; EXPERT TESTIMONY; HUMANS; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; PHOSPHATE-BINDING PROTEINS; PHOSPHORUS; POLYAMINES; RENAL DIALYSIS;

EID: 33749360024     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.14.1897     Document Type: Review

References (87)

1. CENTERS FOR DISEASE CONTROL AND PREVENTION: State-specific trends in chronic kidney failure - United States, 1990 - 2001. MMWR Morb. Mortal. Wkly Rep. (2004) 53:918-920.
2. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of serum phosphorus and calcium × phosphorous product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. (1998) 31:607-617.
3. OWEN WF, LOWRIE EG: C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int. (1998) 54:607-617.
4. GANESH SK, STACK AG, LEVIN NW, HULBERT-SHEARON T, PORT FK: Association of elevated serum POr, CA × POr product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol. (2001) 12:2131-2138.
5. BLOCK GA, KLASSEN PS, LAZARUS JM, OFSTHUN N, LOWRIE EG, CHERTOW GM: Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. (2004) 15:2208-2218.
6. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. (1998) 31(4):607-617.
7. LOWRIE EG, LEW NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am. J. Kidney Dis. (1990) 15(5):458-482.
8. WILLETT WC, BUZZARD M: Nature of Variation in Diet in Nutritional Epidemiology, 2nd Edn. Willett WC (ed) Oxford University Press, New York (1998):33-49.
9. MARKOWITZ GS, STOKES MB, RADHAKRISHNAN J, D'AGATI VD: Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. J. Am. Soc. Nephrol. (2005) 16(11):3389-3396.
10. MARRIOTT WM, HOWLAND J: Phosphate retention as a factor in the production of acidosis in nephritis. Arch. Intern. Med. (1916) 18:708.
11. BRICKER NS, SLATOPOLSKY E, REISS E, AVIOLI LV: Calcium, phosphorous, and bone in renal disease and transplantation. Arch. Intern. Med. (1969) 123:543-553.
12. BRICKER NS: On the pathogenesis of the uremic state. An exposition of the 'trade-off hypothesis.'. N. Engl. J. Med. (1972) 286:1093-1099.
13. MALLUCHE HH, RITZ E et al.: Bone histology in incipient and advanced renal failure. Kidney Int. (1976) 9:355-362.
14. BROWN EM: Mechanisms underlying the regulation of parathyroid hormone secretion in vivo and in vitro. Curr. Opin. Nephrol. Hypertens. (1993) 2:541-551.
15. SARNAK MJ, LEVEY AMJ, LEVEY LS: Epidemiology of cardiac disease in dialysis patients. Semin Dial (1999) 12:69-76.
16. FOLEY RN, PARFREY PS, SARNAK MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. (1998) 32(Suppl. 3): S112-S119.
17. MARCHAIS SJ, METIVIER F, GUERIN AP, LONDON GM: Association of hyperphosphatemia with hemodynamic disturbances in end-stage renal disease. Nephrol. Dial. Transplant. (1999) 14:2178-2183.
18. LONDON GM, MARCHAIS SJ, GUERIN AP et al.: Arterial structure and function in end-stage renal disease. Nephrol. Dial. Transplant. (2002) 17:1713-1724.
19. WONG ND, VO A, ABRAHAMSON D et al.: Detection of coronary artery calcium by ultrafast computed tomography and its relation to clinical evidence of coronary artery disease. Am. J. Cardiol. (1994) 73:223-227.
20. WEXLER L, BRUNDAGE B, CROUSE J et al.: Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association Writing Group. Circulation (1996) 94:1175-1192.
21. JONO S, MCKEE MD, MURRY CE et al.: Phosphate regulation of vascular smooth muscle cell calcification. Circ. Res. (2000) 87:e10-e17.
22. GIACHELLI CM, JONO S, SHIOI A et al.: Vascular calcification and inorganic phosphate. Am. J. Kidney Dis. (2001) 38(Suppl. 1):S34-S37.
23. LONDON GM, PANNER B, MARCHAIS SJ, GUERIN AP: Calcification of the aortic valve in dialyzed patients. J. Am. Soc. Nephrol. (2000) 11:778-783.
24. RUFINO M, GARCIA S, JIMENEZ A et al.: Heart valve calcification and calcium X phosphorus product in hemodialysis patients: analysis of optimum values for its prevention. Kidney Int. (2003) 63(Suppl. 85):S115-S118.
25. WANG AYM, WANG M, WOO J et al.: Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J. Am. Soc. Nephrol. (2003) 13:159-168.
26. FINE A, ZACHARIAS J: Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int. (2002) 61:2210-2217.
27. MAWAD HW, SAWAYA BP, SARIN R et al.: Calcific uremic arteriolopathy in association with low turnover uremic bone disease. Clin. Nephrol. (1999) 52:160-161.
28. MAZHAR AR, JOHNSON RJ, GILLEN D et al.: Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. (2001) 60:324-332.
29. AHMAD A, O'NEAL KD, HOOD AF et al.: Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am. J. Kidney Dis. (2001) 37:1267-1276.
30. BLEYER AJ, CHOI M, IGWEMEZIE B et al.: A case control study of proximal calciphylaxis. Am. J. Kidney Dis. (1998) 32:376-383.
31. MOE SM: Calcific uremic arteriolopathy: a new look at an old disorder. Neph SAP (2004) 3:77-83.
32. HRUSKA KA, TEITELBAUM SL: Mechanisms of disease: renal osteodystrophy. N. Engl. J. Med. (1995) 333:166-175.
33. LOPEZ-HILKER D, DUSSO AS, RAPP NS et al.: Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am. J. Physiol. (1990) 259:F432-F437.
34. LUCAS PA, BROWN RC, WOODHEAD JS, COLES G: 1,25 dihydroxycholecalciferol and parathyroid hormone in advanced renal failure: effects of simultaneous protein and phosphorus restriction. Clin. Nephrol. (1986) 25:7-19.
35. LUMLERTGUL D, BURKE TJ, GILLUM DM et al.: Phosphate depletion arrests progression of chronic renal failure independent of protein intake. Kidney Int. (1986) 29:658-666.
36. HAUT LL, ALFREY AC, GUGGENHEIM S, BUDDINGTON B, SCHRIER N: Renal toxicity of phosphate in rats. Kidney Int. (1980) 17:722-731.
37. PASTAN S, BAILEY J: Dialysis therapy. N. Engl. J. Med. (1998) 338:1428-1437.
38. KOPPLE JD: National Kidney Foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am. J. Kidney Dis. (2001) 37(Suppl. 2):S66-S70.
39. EKNOYAN G, LEVIN A, LEVIN NW, NATIONAL KIDNEY FOUNDATION: Bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. (2003) 42(Suppl. 3):S1-S201.
40. GOTCH FA, PANLILIO F, SERGEYEVA O et al.: A kinetic model of inorganic phosphorus mass balance in hemodialysis therapy. Blood Purif. (2003) 21:51-57.
41. ZEHNDER C, GUTWILLER JP, RENGGLI K: Hemodiafiltration - a new treatment option for hyperphosphatemia in hemodialysis patients. Clinical Nephrol. (1999) 52:152-159.
42. DELMEZ JA, SLATOPOLSKY E, MARTIN KJ, GEARING BN, HARTER HR: Minerals, vitamin D and parathyroid hormone in continuous ambulatory peritoneal dialysis. Kidney Int. (1982) 21:862-867.
43. HSU CH: Are we mismanaging calcium and phosphate metabolism in renal failure? Am. J. Kidney Dis. (1997) 29:641-649.
44. MALLICK NP, GOKAL R: Haemodialysis. Lancet (1999) 353:737-742.
45. LINDSAY RM, HEIDENHEIM P, LEITCH R et al. THE DAILY/NOCTURNAL DIALYSIS STUDY GROUP: Short daily versus long nocturnal hemodialysis. ASAIO (2001) 47:449-455.
46. MUCSI I, HERCZ G, ULDALL R, OUWENDYK M, FRANCOEUR R, PIERRATOS A: Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int. (1998) 53:1399-1404.
47. AL-HEJAILI F, KORTAS C, LEITCH R et al.: Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration. J. Am. Soc. Nephrol. (2003) 14:2322-2328.
48. SHEIKH MS, MAGUIRE JA, EMMETT M et al.: Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro and in vivo study. J. Clin. Invest. (1989) 83:66-73.
49. RAMIREZ JA, EMMETT M, WHITE MG et al.: The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int. (1986) 30:753-759.
50. CLARKSON EM, LUCK VA, HYNSON WV et al.: The effect of aluminum hydroxide on calcium, phosphorus and aluminum balances, the serum parathyroid hormone concentrations and the aluminum content of bone in patients with chronic renal failure. Clin. Sci. (1972) 43:519-531.
51. BERLYNE GM, BEN-ARI J, PEST D et al.: Hyperaluminaemia from aluminum resins in renal failure. Lancet (1970) 2:494-496.
52. CLARKSON EM, LUCK VA, HYNSON WV et al.: The effect of aluminium hydroxide on calcium, phosphorus and aluminium balances, the serum parathyroid hormone concentration and the aluminium content of bone in patients with chronic renal failure. Clin. Sci. (1972) 43:519-531.
53. ALFREY AC, MISHELL JM, BURKS J et al.: Syndrome of dyspraxia and multifocal seizures associated with chronic hemodialysis. Trans. Am. Son Artif. Intern. Organs (1972) 18:257-261.
54. ALFREY AC, LEGENDRE GR, KAEHNY WD: The dialysis encephalopathy syndrome: possible aluminum intoxication. N. Engl. J. Med. (1976) 294:184-188.
55. PIERIDES AM, EDWARDS WG, CULLUM UX, MCCALL JT, ELLIS HA: Hemodialysis encephalopathy with osteomalacic fractures and muscle weakness. Kidney Int. (1980) 8:115-124.
56. MAKOFF DL, GORDON A, FRANKLIN SS, GERSTEIN AR, MAXWELL MH: Chronic calcium carbonate therapy in uremia. Arch. Intern. Med. (1969) 123:15-21.
57. RITZ E: Managing mineral balance in end-stage renal disease. Nephrol. Dial. Transplant. (2004) 19(Suppl. 1):S1-S3.
58. INDRIDASON OS, QUARLES LD, FOR THE DURHAM RENAL OSTEODYSTROPHY STUDY GROUP: Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Kidney Int. (2000) 57:282-292.
59. SLATOPOLSKY E, WEERTS C, LOPEZ-HILKER S et al.: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N, Engl. J. Med. (1986) 315:157-161.
60. SLATOPOLSKY E, WEERTS C, NORWOOD K et al.: Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int. (1989) 36:897-903.
61. CLARKSON EM, EASTWOOD JB, KOUTSAIMANIS KG, DEWARDENER HE: Net intestinal absorption of calcium in patients with chronic renal failure. Kidney Int. (1973) 3:258-263.
62. HARDY P, SECHET A, HOTTELART C et al.: Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artif. Organs (1998) 22:569-5733.
63. TAN CC, HARDEN PN, RODGERS RS: Ranitidine reduces phosphate binding in dialysis patients receiving calcium carbonate. Nephrol. Dial. Transplant. (1996) 11:851-853.
64. MAI ML, EMMETT M, SHEIKH MS et al.: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int. (1989) 36:690-695.
65. EMMETT M, SIRMON MD, KIRKPATRICK WG et al.: Calcium acetate control of serum phosphorus in hemodialysis patients. Am. J. Kidney Dis. (1991) 17:544-550.
66. MORINIERE P, DJERAD M, BOUDAILLIEZ B et al.: Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Comparable efficacy for half the dose of elemental calcium given as acetate without lower incidence of hypercalcemia. Nephron (1992) 60:6-11.
67. CARAVACA F, SANTOS I, CUBERO JJ et al.: Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron (1992) 60:423-427.
68. SCHAEFER K, SCHEER J, ASMUS G et al.: The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study. Nephrol. Dial. Transplant. (1991) 6:170-175.
69. NOLAN CR, CALIFANO JR, BUTZIN CA: Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int. (1990) 38:937-941.
70. DELMEZ JA, KELBER J, NORWORD KY et al.: Magnesium carbonate as a phopphate binder: a prospective, controlled, cross over study. Kidney Int. (1996) 49:163-167.
71. DAMMENT SJP, WEBSTER I: The pharmacology of lanthanum carbonate (Fosrenol®): a new non-aluminum-, non-calcium-based phosphate binder [Abstract]. J. Am. Soc. Nephrol. (2003) 14:204A.
72. HUTCHISON AJ, SPEAKE M, DEWBERRY K, FOX JS: Lanthanum carbonate: a novel non-calcaemic phosphate binder in dialysis patients [Abstract]. Periton. Dial. Int. (1998) 18:S38.
73. FINN WF, JOY MS, HLADIK GA, AND THE LANTHANUM STUDY GROUP: Results of a randomized dose-ranging, placebo controlled study of lanthanum carbonate for reduction of serum phosphate in chronic renal failure patients receiving hemodialysis [Abstract]. J. Am. Soc. Nephrol. (1999) 10:261A.
74. HUTCHISON AJ: Improving phosphate-binder therapy as a way forward. Nephrol. Dial. Transplant. (2004) 19(Suppl. 1):i19-i24.
75. LACOUR B, LUCAS A, AUCHERE D, RUELLAN N, DE SERRE PATEY NM, DRUEKE TB: Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int. (2005) 67:1062-1069.
76. BEHETS GJ, DAMS G, DAMMENT S et al.: Does the phosphate binder lanthanum carbonate affect bone in chronic renal failure rats? J. Am. Soc. Nephrol. (2004) 15:2219-2228.
77. D'HAESE PC, SPASOVSKI GB, SIKOLE A et al.: A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. (2003) 63(Suppl. 85):S73-S78.
78. MALLUCHE HH, GAUGERE MC, WANG G, DEMMENT SJP, WEBSTER I: No evidence of osteomalacia in dialysis patients treated with lanthanum carbonate up to 5 years [Abstract]. J. Am. Soc. Nephrol. (2004) 15:270A.
79. BURKE SL, SLATOPOLSKY EA, GOLDBERG DI: Renagel, a novel calcium- and aluminum-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol. Dial. Transplant. (1997) 12:1640-1644.
80. CHERTOW GM, BURKE SK, RAGGI P, FOR THE TREAT TO GOAL WORKING GROUP: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. (2002) 62:245-252.
81. CHERTOW GM, BURKE SK, LAZARUS JM et al.: Poly[allylamine hydrochloride] (Renagel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am. J. Kidney Dis. (1997) 29:66-71.
82. SLATOPOLSKY EA, BURKE SK, DILLON MA, THE RENAGEL STUDY GROUP: RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int. (1999) 55:299-307.
83. CHERTOW GM, BURKE SK, RAGGI P, TREAT TO GOAL WORKING GROUP: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. (2002) 62:245-252.
84. MITSOPOULOS E, GRIVEAS I, ZANOS S et al.: Increase in serum magnesium level in haemodialysis patients receiving sevelamer hydrochloride. Int. Urol. Nephrol. (2005) 37(2):321-328.
85. CASTRO R, HERMAN A, FERREIRA C, TRAVASSOS F, NUNES-AZEVEDO J, OLIVEIRA M: RenaGel efficacy in severe secondary hyperparathyroidism. Nefrologia (2002) 22:448-455.
86. 2+-sensing receptor from bovine parathyroid. Nature (1993) 366:575-580.
87. BLOCK G, MARTIN KJ: Cinacalcer for secondary hyperparathyroidism in patients receiving hemodialysis. New Engl. J. Med. (2004) 350:1516-1525.